Plain-English translation of NCT04014374 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is watching patients who have received a stem cell transplant and were also treated with mogamulizumab, a medication used for certain blood cancers and skin lymphomas. Researchers want to understand how safe it is to use this medication before or after transplant. They will collect information from patient medical records at several time points over two years.
When patients receive stem cell transplants for blood cancers, doctors sometimes use this medication as part of treatment. However, doctors need to better understand the safety of combining this medication with transplant to make sure it is helping patients without causing unexpected problems.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will not need to visit a clinic or receive new treatment — this is an observational study that reviews your existing medical records. Researchers will collect information about your health at baseline, 100 days after your transplant, and at 6 months, 1 year, and 2 years after transplant. This study may involve both looking back at records you already have and collecting new information going forward.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
United States
Sponsor
Kyowa Kirin, Inc.
Enrollment target
~150 participants
Started
September 2019
Primary completion
February 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Linda J Burns, MD
Kyowa Kirin, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.